239 related articles for article (PubMed ID: 19676044)
21. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells.
Meng X; Li M; Wang X; Wang Y; Ma D
Cancer Sci; 2009 Jun; 100(6):1040-6. PubMed ID: 19385971
[TBL] [Abstract][Full Text] [Related]
22. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
Volm M; Mattern J
Anticancer Res; 1993; 13(6A):2021-5. PubMed ID: 8297109
[TBL] [Abstract][Full Text] [Related]
23. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis.
Xu YH; Zhang GB; Wang JM; Hu HC
Saudi Med J; 2010 Sep; 31(9):980-6. PubMed ID: 20844808
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis.
Chen E; Zeng Z; Bai B; Zhu J; Song Z
Oncotarget; 2016 Aug; 7(35):56526-56539. PubMed ID: 27489355
[TBL] [Abstract][Full Text] [Related]
25. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.
Huang M; Zhu H; Feng J; Ni S; Huang J
Dis Markers; 2015; 2015():986095. PubMed ID: 25691807
[TBL] [Abstract][Full Text] [Related]
26. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer.
Cui F; Wang J; Chen D; Chen YJ
Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061
[TBL] [Abstract][Full Text] [Related]
27. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
28. The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer.
Herpel E; Jensen K; Muley T; Warth A; Schnabel PA; Meister M; Herth FJ; Dienemann H; Thomas M; Gottschling S
Anticancer Res; 2011 Dec; 31(12):4491-500. PubMed ID: 22199321
[TBL] [Abstract][Full Text] [Related]
29. Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma.
Zhang Y; Sun B; Zhao X; Liu Z; Wang X; Yao X; Dong X; Chi J
J Surg Oncol; 2013 Nov; 108(6):414-9. PubMed ID: 23996537
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma.
Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG
Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447
[TBL] [Abstract][Full Text] [Related]
31. The roles of CD133 expression in the patients with non-small cell lung cancer.
Wang D; Wen GM; Hou W; Xia P
Cancer Biomark; 2018; 22(3):385-394. PubMed ID: 29758924
[TBL] [Abstract][Full Text] [Related]
32. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
33. [Expression of CD133 and Notch1 in non-small cell lung cancer and the clinicopathological significance].
Zhou L; Wu S; Yu L; Gong X; Song W; Cheng Z
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Feb; 35(2):196-201. PubMed ID: 25736112
[TBL] [Abstract][Full Text] [Related]
34. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry.
Wu S; Yu L; Wang D; Zhou L; Cheng Z; Chai D; Ma L; Tao Y
BMC Cancer; 2012 Nov; 12():535. PubMed ID: 23170850
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
36. Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB.
Li CY; Li BX; Liang Y; Peng RQ; Ding Y; Xu DZ; Zhang X; Pan ZZ; Wan DS; Zeng YX; Zhu XF; Zhang XS
J Transl Med; 2009 Jul; 7():56. PubMed ID: 19583834
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
39. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I
Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065
[TBL] [Abstract][Full Text] [Related]
40. CD133 is a selective marker of CRC?
Del Rio P; Bonati E; Crafa P; Campanini N; Montana Montana C; Bezer L; Dell'Abate P; Sianesi M
Minerva Chir; 2013 Feb; 68(1):87-95. PubMed ID: 23584268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
